These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Octreotide treatment suppresses malignant somatotrophic pituitary tumor cell growth in rats.
    Author: Kondo H, Takino H, Akino K, Yamasaki H, Yamaguchi Y, Ito M, Eguchi K.
    Journal: Oncol Rep; 2000; 7(5):965-9. PubMed ID: 10948323.
    Abstract:
    We have recently established an in vitro cell line (metastatic mGH3) derived from lymph node metastases of the rat pituitary somatotroph. Here we examined the in vivo effects of octreotide, a somatostatin analog, against malignant pituitary tumors. Wistar-Furth rats (n=8) were inoculated subcutaneously with mGH3 cells while control rats received injections of equal volumes of the vehicle only. Four rats were treated with octreotide three times daily while another group of four rats were treated with saline only. After 6 weeks of treatment, histopathological and immunohistological analyses were performed. The tumor weights of rats treated with octreotide were significantly lighter than those of untreated rats. All rats implanted mGH3, but not administered treatment, developed inguinal lymph node metastases, whereas none of those implanted mGH3 and treated with octreotide developed such metastases. The proportion of PCNA-stained tumor cells was higher in tumors of untreated rats than in those of octreotide-treated rats. However, the proportion of apoptotic cells in the tumor was not different between treated and untreated rats. Our results suggest that octreotide might be potentially effective for invasive and malignant human pituitary tumors by regulating the tumor cell cycle.
    [Abstract] [Full Text] [Related] [New Search]